• Ryan Nachreiner, Jeroen Balledux, Madeline Zieger, Oscar Viegas, and Rajiv Sood.
• Richard M. Fairbanks Burn Unit, Wishard Memorial Hospital, Indiana University, School of Medicine, Indianapolis, Indiana 46202-5124, USA.
• J Burn Care Res. 2006 Mar 1; 27 (2): 237-41.

AbstractNeuroleptic malignant syndrome (NMS) is an uncommon, potentially fatal syndrome that occurs with the use of neuroleptic medications. In view of the rarity of this syndrome and the overlap with the pathophysiologic manifestations of a burn, the burn surgeon may not readily recognize NMS on presentation. We describe the case of a 27-year-old man with 15% TBSA burns who developed NMS as a result of metoclopramide use. Recognition and treatment resulted in a prompt resolution of symptoms. Initial treatment should include immediate withdrawal of all neuroleptic agents, measures aimed at decreasing body temperature, supportive care, and restoration of dopamine balance. Various authors have advocated treatment with various medications, including benzodiazepines, dantrolene, and dopaminergic agents. It is important for burn unit personnel to be aware of this syndrome because the early institution of therapy can be life saving.

18 keywords...

hide…